The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.

ABSTRACT: Despite advances in the management of acute lymphoblastic leukaemia (ALL), current regimens fail to significantly transform outcomes for patients with high-risk subtypes. Advances in genomic analyses have identified novel lesions including mutations in genes that encode chromatin modifiers and those that influence cytokine and kinase signalling, rendering many of these alterations potentially targetable by tyrosine kinase and epigenetic inhibitors currently in clinical use. Although specific genomic lesions, gene expression patterns, and immunophenotypic profiles have been associated with specific clinical outcomes in some cancers, the application of precision medicine approaches based on these data has been slow. This approach is complicated by the reality that patients often harbour mult

SUBMITTER: Tavakoli Shirazi P 

PROVIDER: S-EPMC7028932 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature